Tango Therapeutics, Inc. · NASDAQ:TNGX
Tango Therapeutics — SPAC Merger (April 2021)
14 slides from Tango Therapeutics's SPAC merger presentation, April 2021
Slide 1: Unmasking vulnerabilities in cancer to deliver the next generation of precision medicines
Unmasking vulnerabilities in cancer to deliver the next generation of precision medicines APRIL 2021
Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between BCTG Acquisition Corp. (“BCTG”) and Tango Therapeutics, Inc. (“Tango”) a
Slide 3: Disclaimer (continued)
Disclaimer (continued) Certain information contained in this Presentation relates to or is based on studies, publications, surveys and Tango’s own internal estimates and research. In addition, all of the market data included in this Presentation involve a number of assumptions and limitations, and t
Slide 4: Risk factors
Risk factors • We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from drug sales, and may never become profitable. • We have incurred significant operating losses in recent periods and anticipate that we will incur continued losses for the
Slide 5: Investment highlights
Investment highlights Precision oncology company based on synthetic lethality, combining discovery and clinical development in the same genetic context Expanding oncology target space into tumor suppressor gene loss with a productive, state-of-the-art discovery platform Pipeline of novel drug prog
Slide 6: Tumor suppressor gene loss is a large oncology target space
Tumor suppressor gene loss is a large oncology target space DNA DAMAGE REPAIR EXISTING DRUGS TUMOR SYNTHETIC SUPPRESSOR LETHALITY GENES CELL CYCLE REGULATION • Important drivers of • Currently the only cancer that are way to target tumor inactivated or deleted in suppressor gene loss almost all huma
Slide 7: Tango leadership
Tango leadership LEADERSHIP BOARD OF DIRECTORS Barbara Weber, MD Alan Huang, PhD Daniella Beckman Charles Davis, PhD Alexis Borisy Lesley Calhoun Aaron Davis CEO CSO CFO Pharmaceutical Sciences Heather Jannik Andersen, PhD Bill Mallender, PhD John Maxwell, PhD Reid Huber, PhD Mike Pellini, MD Cary P
Slide 8: Discovery pipeline of novel targets with patient selection strategies
Discovery pipeline of novel targets with patient selection strategies LEAD ANTICIPATED PROGRAM PATIENTS DISCOVERY IND-ENABLING CLINICAL OPTIMIZATION MILESTONES Ph I/II Ph III PRMT5 MTAP-del IND filing 4Q 2021 TNG908 cancers BRCA1-mut USP1 IND filing 2022 cancers STK11-mut TARGET 3 IND filing 2023 lu
Slide 9: TNG908 is an MTA-cooperative PRMT5 inhibitor with 15X selectivity for MTAP-deleted cancer cells
TNG908 is an MTA-cooperative PRMT5 inhibitor with 15X selectivity for MTAP-deleted cancer cells MTAP DELETION FREQUENCY TNG908 HCT116 (colon) MTAP deletion MTAP wild-type TCGA PanCancer Atlas Confidential | 9
Slide 10: PRMT5 first-in-human study in solid tumors with MTAP deletion
PRMT5 first-in-human study in solid tumors with MTAP deletion Malignant peripheral 30-50% nerve sheath MTAP-null tumors Accelerated n ~ 20 approval option DOSE Bladder, lung and 1H 2022 ESCALATION cholangiocarcinoma 15-30% (squamous and non- Planned start of squamous) MTAP-null Any solid tumor n ~ 2
Slide 11: USP1 and BRCA1 are a synthetic lethal pair
USP1 and BRCA1 are a synthetic lethal pair Tango druggable genome CRISPR screen in 13 cell line panel Control USP1i (DMSO) (0.5 µM) USP1 USP1 lead series MDA-MB-436 • USP1 is a de-ubiquitinating BRCA1 mut • enzyme False discovery rate Single agent (DUB)activity that is and combination synthetic leth
Slide 12: Target inhibition reverses immune evasion in STK11 mutant tumors
Target 3 inhibition reverses immune evasion in STK11 mutant tumors Target 3 tool compound in STK11 mutant MC38 mice Tumor growth curve USP1 Target 3 lead series 2500 2500 Tumor Volume (mm3) Control • USP1 is a de-ubiquitinating 2000 2000 a-PD1 enzyme (DUB) that is Target 3i • synthetic Low nanomolar
Slide 13: Use of proceeds from ~$350M SPAC + PIPE financing
Use of proceeds from ~$350M SPAC + PIPE financing Multiple key milestones achievable through 2H 2024 PRMT5 Clinical proof-of-concept data in multiple tumor types PRO FORMA CASH OF ~$550M Enrollment for accelerated approval in rare tumor type (MPNST) PROVIDES RUNWAY Phase I clinical trial compl
Slide 14: Bij TANGO
Bij TANGO therapeutics”